Natalizumab

3 Cited Publications
カスタマーレビュー

Based on 3 publication(s) in Google Scholar

Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4+ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 99.10%
  • CAS 番号: 189261-10-7
  • 分子量:146.19 kDa
  • 保管条件:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • 生物活性
  • 化学情報
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs

Integrin アイソフォーム固有の製品をすべて表示

More
MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00